0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover225.12%IV-87.97%PremiumDec 20, 2024Expiry Date3.51Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8293Delta0.1241Gamma1.09Leverage Ratio-0.0128Theta-0.0028Rho-0.91Eff Leverage0.0023Vega
Mural Oncology Stock Discussion
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune ...
Mural Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.90%)
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
No comment yet